AccuStem Sciences Announces Issuance of US Patent for StemPrintER Test for Patients with Breast Cancer Press Release AccuStem Sciences Announces Issuance of US Patent for StemPrintER Test for Patients with Breast Cancer By accustem|2022-09-13T16:11:48-07:00September 13, 2022|Press Release|
AccuStem Sciences, Inc. Announces Chairman Purchase of Shares Press Release AccuStem Sciences, Inc. Announces Chairman Purchase of Shares By accustem|2022-06-08T15:40:00-07:00April 28, 2022|Press Release|
AccuStem Announces DTC Eligibility Press Release AccuStem Announces DTC Eligibility By accustem|2022-06-09T13:35:05-07:00April 14, 2022|Press Release|
AccuStem Announces Private Placement of Common Stock Press Release AccuStem Announces Private Placement of Common Stock By accustem|2022-06-08T15:45:56-07:00April 5, 2022|Press Release|
AccuStem Sciences, Inc. Announces DTC Eligibility Press Release AccuStem Sciences, Inc. Announces DTC Eligibility By accustem|2022-06-08T21:24:30-07:00March 23, 2022|Press Release|
AccuStem Sciences, Inc. Appoints New Executive Leadership Team Press Release AccuStem Sciences, Inc. Appoints New Executive Leadership Team By accustem|2022-06-09T13:34:47-07:00March 4, 2022|Press Release|
AccuStem’s StemPrintER Demonstrates Prognostic Utility in TransATAC Cohort Press Release AccuStem’s StemPrintER Demonstrates Prognostic Utility in TransATAC Cohort By accustem|2022-06-08T21:43:08-07:00March 1, 2022|Press Release|
Scheme of Arrangement Effective Press Release Scheme of Arrangement Effective By accustem|2022-06-08T22:06:22-07:00December 1, 2021|Press Release|
Court Sanctions the Scheme of Arrangement Press Release Court Sanctions the Scheme of Arrangement By accustem|2022-06-08T21:56:12-07:00November 26, 2021|Press Release|
Results of Shareholder Meetings Press Release Results of Shareholder Meetings By accustem|2022-06-08T22:25:04-07:00November 25, 2021|Press Release|
